Mandeep Behniwal
Psychiatry · Sacramento, CANPI 1679508881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 1,259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,259 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$4K
- AbbVie$4K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- Johnson & Johnson$1K
- plus $8K from 22 others
What the payments were for
- Food & beverage$23,131100%
- Education$630%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 227 | $4,009 |
| AbbVie(2 entities) | 205 | $3,537 |
| Otsuka America Pharmaceutical, Inc. | 109 | $2,328 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 175 | $2,274 |
| Neurocrine Biosciences, Inc. | 57 | $1,501 |
| Johnson & Johnson | 41 | $1,500 |
| Lundbeck LLC | 82 | $1,223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $1,216 |
| Alkermes, Inc. | 41 | $1,142 |
| Vanda Pharmaceuticals Inc. | 57 | $1,077 |
| Teva Pharmaceuticals USA, Inc. | 44 | $899 |
| Indivior Inc. | 50 | $647 |
| Bausch Health US, LLC | 22 | $425 |
| Eisai Inc. | 26 | $359 |
| Almatica Pharma LLC | 19 | $284 |
| Merck | 11 | $206 |
| Avanir Pharmaceuticals, Inc. | 11 | $183 |
| Noven Therapeutics, LLC | 4 | $89 |
| Boehringer Ingelheim | 1 | $77 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Livanova USA, Inc. | 1 | $26 |
| Noven Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,333
- ABILIFY MAINTENA$458
- INGREZZA$366
- INVEGA SUSTENNA$361
- AUSTEDO$339
- ARISTADA INITIO$333
- REXULTI$247
- LATUDA$246
- SPRAVATO$242
- ABILIFY ASIMTUFII$125
- CAPLYTA$124
- VRAYLAR$109
How this compares
$23,194 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $832 |
| Quetiapine Fumarate | 30 | $764 |
| Benztropine Mesylate | 13 | $219 |
| Olanzapine | 14 | $201 |
| Trazodone Hcl | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Sacramento
- David SmithSacramento$588K
- Jacob AdamsSacramento$419K
- Robert McCarronSacramento$136K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.